2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Bioinformatics, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Generative AI, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, CLL, Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2637 Immunoglobulin monitoring and replacement practices during and after blinatumomab therapy: A national survey of Canadian pediatric oncology providers

Julia Miriam Lew, MD, Sarah Alexander, MD2, Gregory Michael Taylor Guilcher, MD, FRCPC, DRCPSC, FAAP3, Pierre-Philippe Piche Renaud, MD4, Nawar Dakhallah, MD5, Kriti Kumar, MD6
1 Hospital for Sick Children, Toronto, Ontario, Canada
2 BC Children's Hospital, Vancouver, British Columbia, Canada
3 Alberta Children's Hospital, Calgary, Alberta, Canada
4 Hospital for Sick Children, Toronto, Ontario, Canada
5 CHU Sainte-Justine, Montreal, Quebec, Canada
6 Hospital for Sick Children, Toronto, Ontario, Canada

Background: Blinatumomab is now incorporated into frontline pediatric B-cell precursor acute lymphoblastic leukemia protocols and can result in secondary hypogammaglobulinemia, which may contribute to infectious complications. National Comprehensive Cancer Network (NCCN) guidance recommends monitoring for hypogammaglobulinemia, repleting with intravenous immunoglobulin (IVIG) for IgG <400 mg/dL or below the age-specific lower limit of normal, and continuing replacement after completion of therapy until B-cell recovery. These recommendations are consensus-based rather than derived from pediatric outcome data, and blinatumomab-specific IgG kinetics are poorly characterized. Real-world concordance with these recommendations, particularly regarding when replacement is stopped, is unknown.

Methods: An electronic REDCap survey was distributed to physicians and nurse practitioners at all 16 Canadian pediatric oncology centers between June and August 2026. Invitations were disseminated through the Canadian Childhood Cancer and Blood Disorders Network (C17) listserv and site-specific contacts; a denominator for invited clinicians was not recoverable. The survey assessed supportive care practices for B-cell-directed immunotherapies; this analysis was restricted to respondents completing blinatumomab items. Data elements included IgG monitoring, IVIG indications, dosing, and discontinuation criteria. Responses were analyzed descriptively at the question level; denominators reflected the number answering each item, as completion of all questions was not required. Select items permitted more than one response.

Results: Thirty-two clinicians from 15 of 16 (94%) centers provided data on IgG monitoring and IVIG replacement after blinatumomab. Respondents were pediatric oncologists (29/32, 91%) and nurse practitioners (3/32, 9%).

Before the first cycle, 29/32 (91%) reported measuring baseline IgG. Thereafter, 7/32 (22%) reported measuring IgG before each subsequent cycle, 22/32 (69%) monthly throughout the remainder of treatment, and 3/32 (9%) only if recurrent viral illness developed.

All respondents answering this item (29/29, 100%) reported administering IVIG for hypogammaglobulinemia, with 28/29 (97%) initiating at IgG <400 mg/dL and 1/29 (3%) using a threshold of <200 mg/dL when infections were absent. None reported using age-specific lower limits of normal. Recurrent viral infections were an additional trigger for 12/29 (41%). Dosing was monthly in all cases, most commonly 500 mg/kg (15/29, 52%), followed by 400 mg/kg (7/29, 24%) and 600 mg/kg (5/29, 17%); 1000 mg/kg and variable dosing were each reported by 1/29 (3%).

Discontinuation criteria (multiple responses permitted) were IgG normalization (28/29, 97%), resolution of infections (14/29, 48%), elapsed time since therapy (8/29, 28%), and B-cell reconstitution (7/29, 24%).

Conclusions: Among Canadian pediatric oncology providers, the principal discordance with NCCN guidance concerns when IVIG is stopped. Only 24% cited B-cell reconstitution—the endpoint anchoring that guidance—whereas 97% cited IgG normalization and 48% cited resolution of infections, suggesting that cessation is driven predominantly by serum IgG and clinical infection status rather than by documented B-cell recovery. By contrast, practice was concordant for the decision to initiate (100%) and for the initiation threshold (97%), whereas dose and monitoring frequency varied. No respondent individualized the threshold by age, such that younger children could be repleted at IgG values within their age-specific reference range. These findings highlight the need for prospective studies evaluating the clinical utility of immunologic monitoring and IVIG replacement in children receiving B-cell-directed immunotherapies.

Julia Miriam Lew, MD: No relevant conflicts of interest to declare.